KDR and cancer: Moreover, the development of dual-inhibitors targeting EGFR and VEGFR2 has recently become a promising strategy for the treatment of diverse types of cancer to overcome problematic drug resistance and low response to selective tyrosine kinase inhibitors (TKIs) and to produce a synergistic effect.15